[PART I — FINANCIAL INFORMATION](index=4&type=section&id=PART%20I%20%E2%80%94%20FINANCIAL%20INFORMATION) This section presents the unaudited condensed financial statements, management's discussion and analysis, and disclosures on market risk and internal controls for the period ended March 31, 2025 [Item 1. Financial Statements (unaudited)](index=4&type=section&id=Item%201.%20Financial%20Statements%20%28unaudited%29) The unaudited condensed financial statements for Q1 2025 show a year-over-year revenue increase to **$485,000**, a reduced net loss of **$1.7 million**, and highlight a significant going concern risk with existing cash expected to fund operations for only the next four months - Auditors express substantial doubt about the company's going concern ability due to a history of operating losses and an accumulated deficit of **$137.8 million** as of March 31, 2025[23](index=23&type=chunk)[24](index=24&type=chunk)[27](index=27&type=chunk) - Existing cash and cash equivalents of **$1.7 million** as of March 31, 2025, are projected to fund operations for only the next four months, necessitating additional financing[29](index=29&type=chunk)[84](index=84&type=chunk) [Condensed Balance Sheets](index=4&type=section&id=Condensed%20Balance%20Sheets) As of March 31, 2025, total assets increased to **$3.6 million** and total stockholders' equity improved to **$2.9 million** due to capital raising, while total liabilities slightly decreased to **$0.7 million** Condensed Balance Sheet Data (in thousands) | Account | March 31, 2025 (unaudited) | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $1,655 | $1,307 | | Total current assets | $3,164 | $2,813 | | **Total assets** | **$3,626** | **$3,278** | | **Liabilities & Equity** | | | | Total current liabilities | $543 | $561 | | **Total liabilities** | **$734** | **$767** | | **Total stockholders' equity** | **$2,892** | **$2,511** | | **Total liabilities and stockholders' equity** | **$3,626** | **$3,278** | [Condensed Statements of Operations and Comprehensive Loss](index=5&type=section&id=Condensed%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) For Q1 2025, revenues increased **17%** year-over-year to **$485,000**, gross profit surged **132%** to **$313,000**, and net loss improved to **$1.7 million** from **$1.8 million** in the prior year Q1 2025 vs Q1 2024 Performance (in thousands, except per share data) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Revenues, net | $485 | $415 | | Cost of sales | $172 | $280 | | **Gross profit** | **$313** | **$135** | | Total operating expenses | $1,976 | $1,978 | | Loss from operations | ($1,663) | ($1,843) | | **Net loss** | **($1,665)** | **($1,832)** | | Net loss per share - basic and diluted | ($1.28) | ($3.56) | [Condensed Statements of Cash Flows](index=6&type=section&id=Condensed%20Statements%20of%20Cash%20Flows) In Q1 2025, net cash used in operating activities was **$1.6 million**, offset by **$1.9 million** from financing activities, resulting in a net increase in cash of **$0.3 million** and ending the period with **$1.7 million** in cash and cash equivalents Cash Flow Summary (in thousands) | Cash Flow Activity | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | ($1,557) | ($1,829) | | Net cash used in investing activities | ($36) | ($2) | | Net cash provided by (used in) financing activities | $1,941 | ($2) | | **Increase (decrease) in cash** | **$348** | **($1,833)** | | **Cash and cash equivalents, end of period** | **$1,655** | **$3,562** | [Notes to Condensed Financial Statements](index=7&type=section&id=Notes%20to%20Condensed%20Financial%20Statements) The notes detail the company's pest fertility control business, including new product launches, significant customer concentration, substantial financing activities, and a material legal contingency involving a trade secret misappropriation lawsuit - The company's lead product is Evolve Rat, launched in January 2024, with Evolve Mouse launched in May 2024, both being minimum risk pesticides exempt from federal EPA registration[19](index=19&type=chunk)[20](index=20&type=chunk)[21](index=21&type=chunk) - In March 2025, a warrant inducement transaction generated **$1.1 million** in gross proceeds from issuing **374,718 shares** and new short-term warrants for over **1.5 million shares**[55](index=55&type=chunk)[57](index=57&type=chunk)[61](index=61&type=chunk) - During Q1 2025, **365,319 shares** were sold under the ATM facility for **$1.2 million** in gross proceeds, with the facility expanded in April 2025[58](index=58&type=chunk)[71](index=71&type=chunk) - Liphatech Inc. is suing the company for breach of contract and trade secret misappropriation, with the company asserting strong defenses despite an uncertain outcome and no accrued settlement amount[69](index=69&type=chunk) - Customer concentration is significant, with one customer representing **31%** of Q1 2025 revenue and **50%** of accounts receivable as of March 31, 2025[67](index=67&type=chunk)[68](index=68&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=21&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management's discussion highlights critical liquidity challenges and reliance on external financing despite a **17%** year-over-year revenue increase driven by the higher-margin Evolve product line, which improved gross profit margin to **64.5%** - The company has a history of significant operating losses, with an accumulated deficit of **$137.8 million** as of March 31, 2025, and expects these losses to continue[80](index=80&type=chunk)[81](index=81&type=chunk) - Existing cash, anticipated revenue, and equity sales are projected to fund operations for only the next four months, making additional financing critical for survival[84](index=84&type=chunk)[96](index=96&type=chunk) - The company may never achieve profitability or positive cash flow and requires continuous capital raising, with failure to do so potentially leading to operational delays or termination[85](index=85&type=chunk)[96](index=96&type=chunk) [Results of Operations](index=24&type=section&id=Results%20of%20Operations) Q1 2025 revenue grew **17%** year-over-year to **$485,000**, primarily from the Evolve product line, which significantly improved gross margin to **64.5%** while total operating expenses remained flat Revenue Breakdown by Product (in thousands) | Product | Q1 2025 Revenue | % of Total | Q1 2024 Revenue | % of Total | | :--- | :--- | :--- | :--- | :--- | | Evolve Rat | $303 | 62% | $250 | 60% | | Evolve Mouse | $81 | 17% | $— | 0% | | ContraPest | $101 | 21% | $165 | 40% | | **Revenues, net** | **$485** | **100%** | **$415** | **100%** | - Gross profit margin increased to **64.5%** in Q1 2025 from **32.5%** in Q1 2024, driven by a product mix shift to the lower-cost Evolve line[88](index=88&type=chunk) - R&D expenses increased by **$48,000** (**13%**) primarily due to personnel realignment to R&D activities[90](index=90&type=chunk) - SG&A expenses decreased by **$50,000** (**3%**) due to reduced headcount and lower personnel costs, partially offset by severance and increased investor relations consulting fees[91](index=91&type=chunk) [Liquidity and Capital Resources](index=27&type=section&id=Liquidity%20and%20Capital%20Resources) The company faces critical liquidity, with **$1.7 million** in cash projected to last only four months, necessitating additional capital to fund operations and R&D, despite **$1.9 million** raised in Q1 2025 from ATM sales and warrant exercises Sources and Uses of Cash (in thousands) | Cash Flow | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :--- | :--- | :--- | | Net cash used in Operating activities | ($1,557) | ($1,829) | | Net cash used in Investing activities | ($36) | ($2) | | Net cash provided by Financing activities | $1,941 | ($2) | | **Cash and cash equivalents, end of period** | **$1,655** | **$3,562** | - Net cash from financing activities in Q1 2025 totaled **$1.9 million**, including **$1.1 million** from the ATM Facility and **$889,000** from warrant exercises[105](index=105&type=chunk) - The company anticipates continued or increased expenses as it focuses on marketing, sales, regulatory approvals, and product development[97](index=97&type=chunk)[103](index=103&type=chunk) [Item 3. Quantitative and Qualitative Disclosures about Market Risk](index=29&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) This section is not applicable as the company is a smaller reporting company - Quantitative and qualitative disclosures about market risk are not applicable for the company[108](index=108&type=chunk) [Item 4. Controls and Procedures](index=29&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including the CEO and CFO, concluded that disclosure controls and procedures were effective as of March 31, 2025, with no material changes to internal control over financial reporting during the quarter - The Chief Executive Officer and Chief Financial Officer concluded that the company's disclosure controls and procedures were effective as of the report period end[111](index=111&type=chunk) - No material changes to internal control over financial reporting occurred during the quarter[112](index=112&type=chunk) [PART II — OTHER INFORMATION](index=30&type=section&id=PART%20II%20%E2%80%94%20OTHER%20INFORMATION) This section details legal proceedings, risk factors, other information, and exhibits filed with the report [Item 1. Legal Proceedings](index=30&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in legal proceedings, including a lawsuit filed by Liphatech Inc. in December 2024, with details provided in Note 10 of the financial statements - The company refers to Note 10, Contingencies, for information on legal proceedings, specifically detailing a lawsuit from Liphatech Inc[114](index=114&type=chunk)[69](index=69&type=chunk) [Item 1A. Risk Factors](index=30&type=section&id=Item%201A.%20Risk%20Factors) There have been no material changes to the risk factors previously disclosed in the company's Annual Report on Form 10-K for the year ended December 31, 2024 - No material changes to the risk factors from the Annual Report on Form 10-K for the year ended December 31, 2024, have been reported[115](index=115&type=chunk) [Item 5. Other Information](index=30&type=section&id=Item%205.%20Other%20Information) During the quarter ended March 31, 2025, no director or officer of the company adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement - No director or officer adopted or terminated a Rule 10b5-1 trading arrangement during Q1 2025[116](index=116&type=chunk) [Item 6. Exhibits](index=30&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including forms of common stock purchase warrants, an inducement letter, and officer certifications - Exhibits filed include forms for Series G Common Stock Purchase Warrants, Placement Agent Warrants, and CEO/CFO certifications[117](index=117&type=chunk) [Signatures](index=31&type=section&id=SIGNATURES) This section contains the official signatures of the company's executive officers, certifying the report's contents - The report was signed on May 8, 2025, by Joel L. Fruendt, President and Chief Executive Officer, and Thomas C. Chesterman, Executive Vice President and Chief Financial Officer[120](index=120&type=chunk)[122](index=122&type=chunk)[123](index=123&type=chunk)

Exhibit 99.1 SenesTech Reports First Quarter 2025 Financial Results 40% Revenue Growth in Evolve , Record Gross Profit Margins of 65%, and Continued Progress Toward Profitability TM SURPRISE, Ariz., May 8, 2025. SenesTech, Inc. (NASDAQ: SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-registered rodent birth control products today announced its financial results for the first quarter ended March 31, 2024. Q1 2025 Highlights Operational and Strategi ...

Core Insights - SenesTech, Inc. reported a 17% increase in revenues for Q1 2025, reaching $485,000 compared to $415,000 in Q1 2024, with Evolve product sales growing 40% year-over-year, now accounting for 79% of total revenue [8][3] - The company achieved a record gross profit margin of 64.5%, up from 32.5% in the same quarter last year [8] - The net loss for Q1 2025 was $1.7 million, slightly improved from a loss of $1.8 million in Q1 2024, while adjusted EBITDA loss improved to $1.5 million from $1.7 million [8] Operational and Strategic Highlights - The Evolve™ Rat and Evolve™ Mouse products are now the largest revenue drivers for SenesTech, reflecting a successful product expansion strategy [3] - E-commerce revenue more than doubled year-over-year, with a 107% increase attributed to improved platform functionality and digital marketing efforts [4] - The company has expanded Evolve deployments in major U.S. municipalities, with positive early adoption in Chicago and a pilot program in New York City [5] International Growth - SenesTech has signed distribution agreements in eleven countries and territories, with product shipments already initiated in The Netherlands, Hong Kong, the UAE, and the Maldives [6] - Regulatory approvals are pending in Australia and New Zealand, with additional launches planned for later in 2025 [6] Financial Performance - The company reported a gross profit of $313,000 for Q1 2025, compared to $135,000 in Q1 2024, indicating improved operational efficiency [17] - Total current assets increased to $3.164 million as of March 31, 2025, up from $2.813 million at the end of 2024 [16] - The company has lowered its breakeven revenue threshold from $12 million to approximately $7 million, indicating a path toward positive cash flow [6]

Company Overview - SenesTech, Inc. is a leader in fertility control for managing animal pest populations, having developed products like ContraPest and Evolve, which are designed to be humane, effective, and sustainable [5]. - The company has entered into an exclusive distribution agreement with Asa Jaya Mandiri LTD (AJM) for the commercialization of Evolve™ in Indonesia, marking its eleventh international distribution agreement [1][4]. Industry Context - Rats are a significant threat to palm oil plantations in Indonesia, causing estimated yield reductions of 5-10% annually, which translates to potential economic losses of USD 540 million to USD 1.08 billion each year, given the palm oil market's value of approximately USD 10.8 billion in 2024 [2]. - The rapid reproduction and adaptability of rats to traditional control methods make long-term population management challenging, highlighting the need for effective fertility control solutions [3]. AJM Profile - Asa Jaya Mandiri LTD (AJM) is a prominent Indonesian trading company with a specialized pest management operation, committed to high quality and standards in its offerings [4][7]. - AJM has over a decade of experience and a diverse portfolio of products sourced globally, enabling it to cater to the unique needs of its customers [7].

Financial Results Announcement - SenesTech, Inc. will report its first quarter 2025 financial results after market close on May 8, 2025 [1] - A conference call is scheduled for the same day at 5:00 p.m. Eastern time to review the results [1] Conference Call Details - Interested parties can access the conference call by dialing (844) 308-3351 or (412) 317-5407 [2] - A live webcast of the conference call will be available on the Company's website [2] Replay Information - A teleconference replay will be available for seven days after the call [3] - A webcast replay will be accessible for 90 days on the Company's website [3] Company Overview - SenesTech is focused on humane management of animal pest populations through fertility control [4] - The company has developed ContraPest, the only U.S. EPA-registered contraceptive for rats, and other minimum risk contraceptives for rodents [4] - The mission is to provide proactive, safe, and sustainable pest management solutions [4]

Core Insights - SenesTech, Inc. is expanding the deployment of its Evolve™ Rat Birth Control in the Wicker Park Bucktown area of Chicago, aiming to manage rodent populations without harmful toxins [1][2] - The initiative is a collaboration between SenesTech and local commerce groups, highlighting a joint effort to address urban pest control challenges [5] - Recent media coverage has noted similar deployments in other urban areas, including a pilot program in New York City and initiatives in Boston and Baltimore [3] Company Overview - SenesTech focuses on humane pest management through fertility control, with products designed to integrate into existing pest management programs, enhancing effectiveness while reducing reliance on traditional poisons [6] - The company aims to create healthier environments and cleaner cities through its innovative solutions [6] Community Engagement - A dedicated informational website has been launched for residents and business owners in the Wicker Park Bucktown area to provide updates and information about the Evolve™ program [4] - Early reports on the consumption of Evolve™ Rat indicate positive feedback, and the company is preparing for further shipments as the deployment area expands [5]

Core Insights - SenesTech, Inc. is participating in a webcast fireside chat at the Lytham Partners 2025 Industrials & Basic Materials Investor Summit on April 1, 2025 [1][2] - The company focuses on humane fertility control solutions for managing rodent populations, aiming to create healthier environments [3] Company Overview - SenesTech's products, such as Evolve rodent birth control, enhance pest management programs while reducing reliance on traditional poisons [3] - The company's mission includes creating cleaner cities, more efficient businesses, and healthier communities through humane and sustainable products [3] Event Details - The fireside chat is scheduled for 3:00 p.m. ET on April 1, 2025, and will be accessible via the conference home page [2] - A replay of the chat will be available through the same links, and one-on-one investor meetings can be arranged upon request [2]

Financial Data and Key Metrics Changes - The company reported a 70% increase in quarterly revenues, reaching a record of $501,000 for Q4 2024, and a 56% increase in annual revenue to $1.9 million [27][8] - Quarterly gross profit margins improved to 61%, up from 44% in the same quarter last year, with gross profit dollars increasing by 136% [31][27] - The adjusted EBITDA loss for the quarter was the smallest in company history, with cash burn expected to decrease from $1.5 million to $1 million per quarter [9][34] Business Line Data and Key Metrics Changes - Evolve Rat accounted for 52% of Q4 sales, with a 365% increase compared to the same quarter last year, while Evolve Mouse represented 24% of sales [27][28] - The historical ContraPest product saw a 51% decline in sales as customers transitioned to Evolve solutions [28] Market Data and Key Metrics Changes - E-commerce sales surged by 206% in Q4 2024, making up 55% of total revenue for the quarter [29][13] - The company has signed distribution agreements in 10 countries, with product shipments already made to Hong Kong, UAE, Netherlands, and Maldives [19][20] Company Strategy and Development Direction - The company aims to achieve cash flow breakeven at an annual revenue threshold of $7 million, down from $12 million historically [9] - Strategic financing completed recently is expected to provide necessary capital to accelerate progress towards profitability [10][25] - Focus areas include expanding e-commerce, municipal programs, and international distribution, with a particular emphasis on the warehousing and distribution sector [16][18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's trajectory, highlighting the successful launch of Evolve products and the positive reception in various markets [11][37] - The company is committed to executing a focused strategy to achieve sustainable long-term success and profitability [36] Other Important Information - The company is implementing cost reduction initiatives expected to lower cash burn by $2 million annually [9] - A new, larger facility in Phoenix is being secured to meet increasing demand without significantly raising facility costs [32] Q&A Session Summary Question: What is the potential growth from the New York pilot program? - Management indicated that the pilot program's success could lead to expansion into additional areas based on initial results [44] Question: What are the sales efforts in the warehousing sector? - The company is moving into ordering pallets of material for deployment in warehousing facilities, indicating a significant market opportunity [46] Question: How is e-commerce contributing to sales? - Management confirmed that advertising and search engine optimization efforts are driving e-commerce sales, which have become a major revenue channel [48] Question: What is the expected contribution from the Lure bait dispenser? - The Lure bait dispenser is seen as a valuable accessory that allows for product use in hard-to-reach areas, generating interest and orders [54] Question: What is the revenue forecast for 2025? - Management refrained from providing specific revenue forecasts but noted that efforts from 2024 are expected to yield results in 2025 [66] Question: What traction has been gained with big box retailers? - The company has seen significant interest from Ace Hardware and is under consideration for warehouse stocking, with orders increasing substantially [68]

Financial Data and Key Metrics Changes - The company reported a record quarterly revenue increase of 70%, reaching $501,000 for Q4 2024, and a 56% increase in annual revenue to $1.9 million [27][8] - Gross profit margins improved to 61% in Q4 2024, up from 44% in the same quarter last year, with gross profit dollars increasing by 136% [31][8] - The adjusted EBITDA loss was the smallest in company history, with cash burn expected to decrease from $1.5 million to $1 million per quarter [9][34] Business Line Data and Key Metrics Changes - Evolve Rat accounted for 52% of Q4 sales, with a 365% increase compared to the same quarter last year, while Evolve Mouse represented 24% of sales [27][28] - ContraPest sales decreased by 51% as customers transitioned to Evolve solutions [28] Market Data and Key Metrics Changes - E-commerce sales surged by 206% in Q4 2024, representing 55% of total revenue for the quarter [28][29] - The company expanded its distribution agreements in 10 countries, with significant orders from cities like New York and Baltimore [19][15] Company Strategy and Development Direction - The company aims to achieve cash flow breakeven at an annual revenue threshold of $7 million, down from $12 million historically [9] - Strategic financing completed is expected to accelerate progress towards profitability [10][24] - Focus on expanding into municipal markets, warehousing, and international distribution as key growth drivers [22][18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's trajectory, highlighting the successful launch of Evolve products and the potential for growth in various markets [11][37] - The company is committed to a focused strategy that emphasizes cost efficiencies and sustainable long-term success [36] Other Important Information - The company is implementing new initiatives to reduce cash burn by $2 million annually and has secured a larger facility to meet increasing demand [9][32] - The introduction of the Lure bait dispenser is expected to enhance product accessibility, although it is not projected to be a high revenue item [53][54] Q&A Session Summary Question: Visibility on New York pilot program - Management indicated that the pilot program in New York will start in April, with potential for expansion based on initial success [42][44] Question: Sales efforts in warehousing and distribution - The company is seeing increased orders from warehousing facilities, particularly in food production, where traditional poisons are not feasible [46][47] Question: E-commerce sales strategy - Management confirmed that advertising and search engine optimization efforts are in place to drive e-commerce sales, with significant growth noted on platforms like Amazon [48][49] Question: Clarification on cash burn reduction - The reduction from $1.5 million to $1 million was clarified as a decrease in cash burn or adjusted EBITDA [50][52] Question: Contribution of Lure bait dispenser - The Lure bait dispenser is seen as a valuable accessory that allows for product use in hard-to-reach areas, generating interest and orders [53][54] Question: Revenue growth from recent contracts - Management noted that regulatory approvals and field trials are necessary before significant revenue contributions can be expected from new contracts [62][64] Question: Traction with big box retailers - The company has seen significant interest from retailers like Ace Hardware, with plans to expand into their warehouses [68][69] Question: Marketing plans for increasing awareness - A comprehensive marketing plan is in place to promote the product's success in municipalities and through social media [71][73] Question: Manufacturing capacity and cost savings - The company has built its supply chain to handle increased demand without constraints, with ongoing efforts to improve manufacturing efficiencies [77][79]

Market Focus and Product Development - The rat control market is considered sufficient for the company's near-term focus[18]. - The company is focused on gaining market acceptance and commercial viability for its products, including ContraPest and Evolve[18]. - The company believes that its technology can be applied to other mammalian species, which may open new market opportunities[21]. - The company expects expenses to continue increasing as commercialization activities advance[18]. - The success of the company's research and development efforts is critical for future performance and product commercialization[21]. Regulatory and Compliance Issues - The company acknowledges the risks associated with obtaining regulatory approval for its product candidates[21]. - The company anticipates that first and second generation anti-coagulant rodenticides will face increased scrutiny and potential restrictions[18]. - The company asserts that Evolve qualifies for exemption from registration as a minimum risk pesticide under EPA regulations[18]. - The company is subject to compliance with Nasdaq's continued listing requirements, which is vital for maintaining its market presence[21]. - The company files reports with the SEC, ensuring transparency and compliance with information requirements[23]. Financial and Operational Risks - The company faces risks that may cause actual results to differ materially from forward-looking statements, including market acceptance of products and regulatory approvals[21]. - The company acknowledges potential product liability lawsuits that could incur substantial liabilities and limit product commercialization[21]. - The company is concerned that raising additional capital may dilute existing stockholders and restrict operations[21]. - The company recognizes that its share price is volatile, which could lead to securities class action litigation[21]. Human Resources and Talent Management - The company plans to utilize stock-based awards to attract and retain talented employees[18]. - Retaining and attracting key personnel is essential for the company's growth and operational development[21]. - The company emphasizes the importance of establishing an effective sales force and marketing infrastructure to generate significant revenue[21]. Research and Field Studies - The company believes that field research demonstrates more than 90% reduction in rat populations when integrated with pest management protocols[18]. - The company aims to establish fertility control as a standard tool in pest management across all verticals[18].